Laura Prendergast
Stock Analyst at Stifel Nicolaus
(3.96)
# 1,840
Out of 5,125 analysts
98
Total ratings
41.6%
Success rate
11.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Maintained: Buy | $15 | $2.20 | +581.82% | 6 | Nov 11, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $230 | $193.10 | +19.11% | 26 | Nov 9, 2026 | |
| COGT Cogent Biosciences | Reiterated: Buy | $45 | $31.66 | +42.14% | 11 | Nov 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $8.89 | +102.47% | 4 | Oct 29, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $48 | $31.72 | +51.32% | 2 | Oct 26, 2026 | |
| IMTX Immatics | Reiterated: Buy | $15 | $6.43 | +133.46% | 2 | Oct 26, 2026 | |
| TNGX Tango Therapeutics | Reiterated: Buy | $40 → $55 | $24.29 | +126.43% | 11 | Oct 23, 2026 | |
| FHTX Foghorn Therapeutics | Reiterated: Buy | $12 → $5 | $1.90 | +163.16% | 8 | Oct 1, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $48 → $30 | $7.26 | +313.22% | 2 | Sep 14, 2026 | |
| ERAS Erasca | Reiterated: Buy | $30 | $15.50 | +93.55% | 12 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $10.18 | +371.51% | 2 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $1.60 | +401.57% | 7 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $9.99 | n/a | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $8.80 | n/a | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $1.36 | n/a | 1 | Aug 14, 2024 |
BridgeBio Oncology Therapeutics
Nov 11, 2026
Maintained: Buy
Price Target: $15
Current: $2.20
Upside: +581.82%
Revolution Medicines
Nov 9, 2026
Reiterated: Buy
Price Target: $230
Current: $193.10
Upside: +19.11%
Cogent Biosciences
Nov 6, 2026
Reiterated: Buy
Price Target: $45
Current: $31.66
Upside: +42.14%
ORIC Pharmaceuticals
Oct 29, 2026
Reiterated: Buy
Price Target: $18
Current: $8.89
Upside: +102.47%
IDEAYA Biosciences
Oct 26, 2026
Reiterated: Buy
Price Target: $48
Current: $31.72
Upside: +51.32%
Immatics
Oct 26, 2026
Reiterated: Buy
Price Target: $15
Current: $6.43
Upside: +133.46%
Tango Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $40 → $55
Current: $24.29
Upside: +126.43%
Foghorn Therapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $12 → $5
Current: $1.90
Upside: +163.16%
Olema Pharmaceuticals
Sep 14, 2026
Reiterated: Buy
Price Target: $48 → $30
Current: $7.26
Upside: +313.22%
Erasca
Aug 17, 2026
Reiterated: Buy
Price Target: $30
Current: $15.50
Upside: +93.55%
Aug 17, 2026
Reiterated: Buy
Price Target: $48
Current: $10.18
Upside: +371.51%
Aug 6, 2026
Reiterated: Buy
Price Target: $8
Current: $1.60
Upside: +401.57%
Jul 29, 2025
Reiterated: Buy
Price Target: $12
Current: $9.99
Upside: n/a
Feb 13, 2025
Reiterated: Buy
Price Target: $4
Current: $8.80
Upside: n/a
Aug 14, 2024
Upgraded: Buy
Price Target: $16
Current: $1.36
Upside: n/a